Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

V-9302

V-9302 is a competitive antagonist of transmembrane glutamine flux. V-9302 selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 inhibits ASCT2-mediated glutamine uptake (IC50=9.6 μM) in HEK-293 cells[1].

Product Specifications

CAS Number

[1855871-76-9]

UNSPSC

12352005

Target

ASCT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/v-9302.html

Purity

99.46

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : < 0.1 mg/mL (ultrasonic)

Smiles

O=C(O)[C@@H](N)CCN(CC1=CC=CC=C1OCC2=CC=CC(C)=C2)CC3=CC=CC=C3OCC4=CC=CC(C)=C4

Molecular Formula

C34H38N2O4

Molecular Weight

538.68

References & Citations

[1]Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacyin preclinical models. Nat Med. 2018 Feb;24 (2) :194-202.|[2]Jin H, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9:e56749. Published 2020 Oct 5.|[3]Edwards DN, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131 (4) :e140100.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

ASCT2

Citation 01

Adv Sci (Weinh) . 2024 Dec 16:e2411479.|Adv Sci (Weinh) . 2025 Aug 10:e07057.|Autophagy. 2025 Jul 23:1-16.|Biomaterials. 2025 Sep 17:326:123726.|bioRxiv. 2024 July 05.|bioRxiv. 2025 Jul 31:2025.07.28.667320.|Cell Death Dis. 2024 Feb 5;15 (2) :111.|Cell Metab. 2022 Dec 6;34 (12) :1999-2017.e10.|Cell. 2024 Oct 31;187 (22) :6251-6271.e20.|FASEB J. 2025 Jul 15;39 (13) :e70774.|Front Pharmacol. 2021 May 14;12:671328.|J Biol Chem. 2022 Apr;298 (4) :101753.|J Control Release. 2023 May:357:460-471.|J Gastroenterol. 2025 Oct 8.|J Virol. 2025 Nov 25;99 (11) :e0098525.|Magn Reson Imaging. 2022 Nov:93:189-194.|Nano Today. 2025 Apr.|Nat Immunol. 2024 Oct;25 (10) :1845-1857.|Npj Imaging. 2025 Aug 1;3 (1) :34.|Pharmaceutics. 2024 Jun 29;16 (7) :877.|Proc Natl Acad Sci U S A. 2024 Mar 26;121 (13) :e2319429121.|University of Maryland. 2024.|University of Regensburg. 2024 Jul 18.|Biochem Pharmacol. 2025 Feb 7:116796.|Biochem Pharmacol. 2025 Jun 7:117047.|J Nanobiotechnology. 2022 May 6;20 (1) :216.|Research Square Print. 2023 Jan 31.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

ATG5 (NM_001286107) Human Untagged Clone

SC334382 10 µg

ATG5 (NM_001286107) Human Untagged Clone

Ask

Dmrt2 (NM_145831) Mouse Tagged Lenti ORF Clone

MR225591L4 10 µg

Dmrt2 (NM_145831) Mouse Tagged Lenti ORF Clone

Ask

TRP2 (DCT) Human shRNA Plasmid Kit (Locus ID 1638)

TL313546 1 Kit

TRP2 (DCT) Human shRNA Plasmid Kit (Locus ID 1638)

Ask

Recombinant Vibrio vulnificus UDP-3-O-acylglucosamine N-acyltransferase (lpxD)

MBS1445067-01 0.02 mg (E-Coli)

Recombinant Vibrio vulnificus UDP-3-O-acylglucosamine N-acyltransferase (lpxD)

Ask

Recombinant Vibrio vulnificus UDP-3-O-acylglucosamine N-acyltransferase (lpxD)

MBS1445067-02 0.02 mg (Yeast)

Recombinant Vibrio vulnificus UDP-3-O-acylglucosamine N-acyltransferase (lpxD)

Ask

Recombinant Vibrio vulnificus UDP-3-O-acylglucosamine N-acyltransferase (lpxD)

MBS1445067-03 0.1 mg (E-Coli)

Recombinant Vibrio vulnificus UDP-3-O-acylglucosamine N-acyltransferase (lpxD)

Ask